Company intelligence / Profile preview

Thios Pharmaceuticals

Emeryville, California, United Statescell.com ↗

Ownership: Private
Development stage: Other

Overview

Thios Pharmaceuticals developed therapies targeting biological sulfation pathways, with a lead program focused on an adhesion-blocking antibody for chronic inflammatory diseases. The company in‑licensed TS1 (rPSGL-Ig), a clinical-stage compound from Wyeth, intended for acute sickle cell disease crises and prevention of delayed graft function post-kidney transplant. The company is now out of business and did not advance any products to market.

Therapeutic areas: PulmonologyHematologyOncologyNephrologyImmunology
Modalities: Monoclonal antibodyHumanized single-chain antibody fragmentSmall molecule
Industry: Biotech

Drug pipeline

1 asset

rPSGL-Ig

Partnerships

Wyeth (licensing agreement for TS1/rPSGL-Ig)

Beyond the preview

Go deeper on Thios Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thios Pharmaceuticals.

Explore the full profile